The study, which followed 195 patients recently diagnosed with multiple myeloma (MM), found that a negative PET/CT scan six months after diagnosis and induction therapy was significantly linked with improved survival.

The new equipment, which initially will be used to treat prostate and neuroendocrine tumors, is expected to be operational in July.

In pediatric care settings, hybrid PET/MR imaging combines “exquisite soft-tissue information obtained by MR imaging with functional information provided by PET.”

The FDA has approved a lab test for evaluating cognitively impaired adults who may be in the early stages of Alzheimer’s disease.

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

The findings could help clinicians manage patients’ treatment when the origin of axillary lymphadenopathy is of concern, experts suggested. 

The therapeutic combination of 177Lu-PSMA-617 with idronoxil (NOX66) reduced PSA levels in 86% of study participants.

Experts suggest that their findings could help differentiate between dementia and other neurological diseases that have similar symptoms.